关键词：特发性肺纤维化；间质性组肺疾病；肺部疾病；高分辨率计算机；断层扫描；Nintedanib；吡非尼酮
摘 要：Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding the disease

Pathogenesis

Signs and symptoms

Diagnosis

Management

Epidemiology

PART 06: Pipeline analysis

Lebrikizumab

Tipelukast

Tralokinumab

FG-3019

Simtuzumab

BMS-986020

AF-219

SAR156597

BG00011

PRM-151

PBI-4050

PART 07: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 08: Market segmentation by ROA

Oral

Parenteral

PART 09: Market segmentation by drug class

Systemic corticosteroids

Immunosuppressants

Tyrosine kinase inhibitors

Anti-fibrotic agents

PART 10: Geographical segmentation

Global idiopathic pulmonary fibrosis market by

geographical segmentation 2015-2020

Idiopathic pulmonary fibrosis market in Americas

Idiopathic pulmonary fibrosis market in EMEA

Idiopathic pulmonary fibrosis market in APAC

PART 11: Market drivers

Special regulatory designations for pipeline candidates

Growth in patient population

Unmet medical needs

PART 12: Impact of drivers

PART 13: Market challenges

Unknown disease etiology

Lack of proper diagnosis

Increased use of off-label and alternative therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends

Patient assistance programs

Increase in M&A

Rise in public awareness

PART 16: Vendor landscape

Competitive scenario

Market share analysis 2015

Baxter International

Boehringer Ingelheim

F Hoffmann-La Roche

Prometheus Laboratories

Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio